Abstract: A pharmaceutical composition for use in promoting wound healing and/or accelerating closure of an open wound in a subject in need thereof is disclosed. The composition comprises a therapeutically effective amount of a recombinant polypeptide comprising an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO: 2; and a pharmaceutically acceptable vehicle, carrier, diluent, excipients, and/or salt.

Abstract: A pharmaceutical composition for use in promoting wound healing and/or accelerating closure of an open wound in a subject in need thereof is disclosed. The composition comprises a therapeutically effective amount of a recombinant polypeptide comprising an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO: 2; and a pharmaceutically acceptable vehicle, carrier, diluent, excipients, and/or salt.

Abstract: The present invention relates to a method for treating a bone loss disease, condition, or disorder in a subject in need thereof, comprising administering to said subject a pharmaceutically effective amount of a composition comprising thrombomodulin lectin-like domain (TMD1).

Abstract: A method for blocking, inhibiting and/or decreasing cluster of differentiation 14 (CD14) function, CD14-mediated cellular response and/or treating CD14-mediated pathological conditions is disclosed. The method comprises administering to a subject in need thereof a pharmaceutical composition comprising: (a) a therapeutically effective amount of a recombinant protein comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 1, wherein the recombinant protein does not comprises a lectin-like domain 1 of a human thrombomodulin; and (b) a pharmaceutically acceptable vehicle, carrier, diluent, excipients, and/or salt.

Abstract: The present invention relates to a method for treating a bone loss disease, condition, or disorder in a subject in need thereof, comprising administering to said subject a pharmaceutically effective amount of a composition comprising thrombomodulin lectin-like domain (TMD1).

Abstract: A method for blocking, inhibiting and/or decreasing cluster of differentiation 14 (CD14) function, CD14-mediated cellular response and/or treating CD14-mediated pathological conditions is disclosed. The method comprises administering to a subject in need thereof a pharmaceutical composition comprising: (a) a therapeutically effective amount of a recombinant protein comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 1, wherein the recombinant protein does not comprises a lectin-like domain 1 of a human thrombomodulin; and (b) a pharmaceutically acceptable vehicle, carrier, diluent, excipients, and/or salt.

Abstract: A pharmaceutical composition comprising an effective amount of a mutant thrombomodulin is disclosed. The mutant thrombomodulin comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 2 and has residues corresponding to Ala364 and Ala391 of SEQ ID NO: 2. The mutant thrombomodulin has little or no protein C activation activity, and is effective in promoting wound healing and accelerating closure of an open wound in a diabetic.

Abstract: A method for pharmacological prevention and suppression of aortic aneurysm development is disclosed. The method comprises administering a therapeutically effective amount of recombinant thrombomodulin to a subject in need thereof. The recombinant thrombomodulin prevents formation and/or retards progression of an aortic aneurysm.

Abstract: A pharmaceutical composition comprising an effective amount of a mutant thrombomodulin is disclosed. The mutant thrombomodulin comprises an ammo acid sequence that is at least 80% identical to SEQ ID NO: 2 and has residues corresponding to Ala364 and Ala391 of SEQ ID NO: 2. The mutant thrombomodulin has little or no protein C activation activity, and is effective in promoting wound healing and accelerating closure of an open wound in a diabetic.

Abstract: A method for pharmacological prevention and suppression of aortic aneurysm development is disclosed. The method comprises administering a therapeutically effective amount of recombinant thrombomodulin to a subject in need thereof. The recombinant thrombomodulin prevents formation and/or retards progression of an aortic aneurysm.

Abstract: A method for treating ischemia that would benefit from angiogenesis is disclosed. The method comprises administering to a subject in need thereof a composition comprising: a) a fragment of human thrombomodulin in a therapeutically effective amount; and b) a pharmaceutically acceptable carrier; wherein the fragment comprises the amino acids Ala242 to Ser515 of SEQ ID NO: 2.

Abstract: The invention relates to a method for treatment of wound healing, comprising administering to a patient in need of such treatment with an effective amount of a polypeptide comprising amino acid sequence or a conservative variant thereof having EGF-like domain of thrombomodulin. The invention also relates to a composition for the use of accelerating wound healing, comprising a polypeptide comprising amino acid sequence or a conservative variant thereof having EGF-like domain of thrombomodulin.

Abstract: The present invention relates to a method for binding Lewis Y antigen of a subject, comprising administering to the subject an effective amount of N-terminal lectin-like domain of thrombomodulin (TMD1), or its analogues.

Abstract: The present invention relates to a method for providing bactericide or bacteriostatic, especially for treating disease due to bacterial infection. The method comprising administering a patient in need of such treatment a therapeutically effective amount of a compound of dextromethorphan or naloxone or a pharmaceutically acceptable salt or an analog thereof. The compound is applied to skin or mucosal surface of the patient. The invention also relates to a method of treating inflammation caused by suppressing secretion of TNF-?, IL-6, or MCP-1 from macrophage comprising administering a patient in need of such treatment a therapeutically effective amount of NADPH oxidase inhibitor.

Abstract: The present invention aims at converting factor IX into a molecule with enhanced activity which provides an alternative for replacement therapy and gene therapy for hemophilia B. Using recombinant techniques, factor IX with replacement at positions 86, 277, and 338 exhibits better clotting activity than recombinant wild type factor IX.

Abstract: A method for treating ischemia that would benefit from angiogenesis is disclosed. The method comprises administering to a subject in need thereof a composition comprising: a) a fragment of human thrombomodulin in a therapeutically effective amount; and b) a pharmaceutically acceptable carrier; wherein the fragment comprises the amino acids Ala242 to Ser515 of SEQ ID NO: 2.

Abstract: The present invention relates to a method for preventing or treating a cardiovascular disease.

Abstract: The invention relates to a composition for promoting angiogenesis, for controlling DNA synthesis of a cell, and for controlling chemotactic motility of a cell. The invention also relates to a method for treating ischemia diseases.

Abstract: A method for binding Lewis Y antigen of a subject, comprising administering to the subject an effective amount of nucleotide sequence encoding N-terminal lectin-like domain of thrombomodulin (TMD1), or its analogues; and a method of detecting cancer cells, Gram-negative bacteria or LPS which over-express the Lewis Y antigen in a sample from a subject.

Abstract: The present invention aims at converting factor IX into a molecule with enhanced activity which provides an alternative for replacement therapy and gene therapy for hemophilia B. Using recombinant techniques, factor IX having substitution of amino acid residue of SEQ ID NO: 7 at amino acid position selected from the group consisting of 86, 277, and 338 (exclude the circumstance of a single substitution at amino acid position 338) exhibits better clotting activity than recombinant wild type factor IX.